News About: Pharm. Affairs
Narcotic appetite suppressants sold 200 million units last year
Unlike the Ministry of Food and Drug Safety’s(MFDS) argument that sales of phentermine & phendimetrazine are not increasing anymore as a justification to limit approval of narcotic appetite suppressants(phentermine & ...
“It’ll be a jackpot to launch Champix generic,’ leading patent challenges
Since Pfizer’s antismoking treatment, ‘Champix(varenicline tartrate)’ become a gigantic product with the government’s drug price support, Korean pharmaceutical companies have tried to launch its generic.
However, it...
“Korean bio-pharma investment market has gigantic bubble”
I was criticized a part of foreign countries indicated huge bubble is created on the Korean biopharmaceutical market because of excessive expectations.
At the 2016 Bio-Converged Technology Conference hosted by the Mi...
Relaxation of policy to obligate to turn in bioequivalence test data on drug reassessment
Data of bioequivalence tests must have been turned in reassessment of drugs so far, but a regulation will be relaxed that it need to conditionally be turned in depending on target products for the reassessment.
The M...
Reason why melanoma therapy Zelboraf failed to be registered for insurance benefit
A Roche Korea’s metastatic melanoma treatment ‘Zelboraf(vemurafenib)’ is a drug which still has not been registered in the drug insurance benefit list for more than 4 years after acquiring commercialization approval i...
Will Avastin be administered in ophthalmology field having no approval?
The government is working on legislating an act to allow hospitals and clinics having no IRB(Institutional Review Board) to widely use pharmaceutical products officially notified by President of the Health Insurance R...
Samsung Bioepis begins to nullify Herceptin’s patent
Samsung Bioepis has started to prepare for a launch of Herceptin(generic name: trastuzumab) biosimilar, a breast cancer treatment, in Korea.
According to the Intellectual Property Tribunal, Samsung Bioepis filed a (...
Countdown for AIDS treatment overcoming ‘Stribild’ to launch in Korea
A Gilead Sciences’ new 4-substance complex drug ‘Genvoya’ acquired approval to commercialize in Korea. Thus, Gilead is expected to consolidate its position in the HIV treatment market.
According to the industry conc...
CorePharm succeeds in avoiding Astellas’ patent by salt modification
While a series of domestic companies’ challenges to substance patents all went in vein after implementation of the Patent Linkage System on March 2015, a ruling was made in favor of a Korean challenger at the defensiv...
‘Boots’ shop-in-shop pharmacy visualized to open on March next year
Opening a Boots’ pharmacy is being visualized inside of ‘Starfield,’ the Shinsegae Group’s shopping theme park located in Hanam-si, Gyeonggi-do.
According to a person concerned to the region on the 19th, Boots is pla...
